We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.72B
AUM Growth
–
Cap. Flow
+$4.69B
Cap. Flow %
99.51%
Top 10 Hldgs %
37.69%
Holding
127
New
123
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$272M
2
GILD icon
Gilead Sciences
GILD
+$251M
3
BIIB icon
Biogen
BIIB
+$219M
4
MRK icon
Merck
MRK
+$193M
5
VTRS icon
Viatris
VTRS
+$149M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
2 Financials 2.05%
3 Technology 0.14%
4 Utilities 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
26
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$73.2M 1.55%
+4,520,800
New +$140M
MDVN
27
DELISTED
MEDIVATION, INC.
MDVN
$72.4M 1.54%
+2,944,200
New +$74.1M
EXAS
28
DELISTED
Exact Sciences
EXAS
$65.4M 1.39%
+4,701,900
New +$51.1M
IPXL
29
DELISTED
Impax Laboratories, Inc.
IPXL
$65M 1.38%
+3,260,600
New +$57.9M
MOH icon
30
Molina Healthcare
MOH
$10.6B
$61.9M 1.31%
+1,665,000
New +$58.8M
WCRX
31
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
$54.8M 1.16%
+2,753,100
New +$46.6M
SPY icon
32
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
$48.1M 1.02%
+300,000
New +$48.3M
NXTM
33
DELISTED
NxStage Medical Inc.
NXTM
$46M 0.98%
+3,221,100
New +$40.5M
ATRS
34
DELISTED
Antares Pharma, Inc.
ATRS
$38.3M 0.81%
+9,199,000
New +$35.5M
CI icon
35
Cigna
CI
$79.1B
$31M 0.66%
+427,000
New +$28.8M
ALGN icon
36
Align Technology
ALGN
$12.8B
$30.5M 0.65%
+824,000
New +$28.4M
AFFX
37
DELISTED
Affymetrix Inc
AFFX
$28.3M 0.6%
+6,375,400
New +$24.2M
WCG
38
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
$27.8M 0.59%
+500,000
New +$27.9M
MAKO
39
DELISTED
MAKO SURGICAL CORP COM
MAKO
$26.7M 0.57%
+2,212,100
New +$25.1M
XBI icon
40
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$26.1M 0.55%
+750,000
New +$26.4M
AGN
41
DELISTED
Allergan Inc
AGN
$25.4M 0.54%
+302,000
New +$31.3M
ACAD icon
42
Acadia Pharmaceuticals
ACAD
$4.45B
$23.5M 0.5%
+1,293,000
New +$17.8M
ARRY
43
DELISTED
Array Biopharma Inc
ARRY
$22.1M 0.47%
+4,865,000
New +$26.2M
LAB icon
44
Standard BioTools
LAB
$325M
$22M 0.47%
+1,262,708
New +$22.2M
CNC icon
45
Centene
CNC
$31.3B
$21.9M 0.47%
+1,673,200
New +$20.3M
HNT
46
DELISTED
HEALTH NET INC
HNT
$20.7M 0.44%
+650,000
New +$19.6M
XNPT
47
DELISTED
XENOPORT, INC.
XNPT
$20M 0.42%
+4,040,800
New +$24.5M
NTUS
48
DELISTED
Natus Medical Inc
NTUS
$19.5M 0.41%
+1,427,000
New +$19.4M
WCRX
49
CALL
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
$19.1M 0.41%
+961,100
New +$16.3M
IQV icon
50
IQVIA
IQV
$40.5B
$18.7M 0.4%
+440,000
New +$19.3M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Amgen: 2,619,400 shares worth $258M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Financials and Technology.

  • OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
  • OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
  • OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.

Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.